Comparison of N-terminal pro-atrial natriuretic peptide and atrial natriuretic peptide in human plasma as measured with commercially available radioimmunoassay kits.
暂无分享,去创建一个
[1] K. Nakao,et al. γ-Atrial natriuretic polypeptide (γANP)-derived peptides in human plasma: Cosecretion of N-terminal γANP fragment and αANP , 1988 .
[2] S. Bloom,et al. Increase in plasma concentrations of cardiodilatin (amino terminal pro-atrial natriuretic peptide) in cardiac failure and during recumbency. , 1988, British heart journal.
[3] T. Benraad,et al. A sensitive radioimmunoassay of atrial natriuretic peptide in human plasma, using a tracer with an immobilized glycouril agent. , 1987, Clinica chimica acta; international journal of clinical chemistry.
[4] F. Boomsma,et al. Stability of human plasma atrial natriuretic peptide during storage at −80°C , 1993 .
[5] N. Markandu,et al. N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126). , 1994, Clinical science.
[6] K. Imataka,et al. Plasma levels of atrial natriuretic factor in patients with congestive heart failure. , 1985, The New England journal of medicine.
[7] S. Yusuf,et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.
[8] C. Hall,et al. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine. , 1995, Circulation.
[9] N. Markandu,et al. Concentrations of N-terminal ProANP in human plasma: evidence for ProANP (1-98) as the circulating form. , 1990, Clinica chimica acta; international journal of clinical chemistry.
[10] P. Koistinen,et al. Effect of physical exercise in hypobaric conditions on atrial natriuretic peptide secretion. , 1992, The American journal of physiology.
[11] K. Minaker,et al. Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. , 1992, JAMA.
[12] D. vesely,et al. The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. , 1989, Circulation.
[13] A. Struthers,et al. N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro. , 1995, Circulation.
[14] I. Tikkanen,et al. PLASMA ATRIAL NATRIURETIC PEPTIDE IN CARDIAC DISEASE AND DURING INFUSION IN HEALTHY VOLUNTEERS , 1985, The Lancet.
[15] P. Mathisen,et al. Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. , 1993, Scandinavian journal of clinical and laboratory investigation.
[16] O. Vuolteenaho,et al. Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. , 1994, American heart journal.
[17] G. Lamas,et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.
[18] J. Sundsfjord,et al. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. , 1988, The Journal of clinical endocrinology and metabolism.
[19] K. Bailey,et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction , 1993, The Lancet.
[20] A. D. de Bold,et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.